China National Pharmaceutical Group Co., Ltd (Sinopharm) is reportedly considering a bid to acquire Shanghai-based BBI Life Sciences Corp., with a potential deal valued at over USD 1 billion, according to Bloomberg. The news cites insider sources stating Sinopharm has held preliminary talks with BBI’s founding Wang family, while other suitors are also evaluating a purchase.
Company Background
Founded in 2013, BBI Life Sciences offers a suite of products and services, including DNA synthesis (oligonucleotides and genes), genetic engineering, life science research consumables, and protein/antibody products. The firm was listed on the Hong Kong Stock Exchange in 2014 but went private in 2020 via a HKD 845 million (USD 108 million) buyout by the Wang family.
Acquisition Interest
Sinopharm’s interest in BBI underscores the state-owned pharma giant’s push to expand its biotech footprint. The acquisition, if completed, would bolster Sinopharm’s capabilities in genetic engineering and life science tools. Details of the talks remain under wraps, with no official confirmation from either party.-Fineline Info & Tech
